JP2007509186A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509186A5 JP2007509186A5 JP2006537550A JP2006537550A JP2007509186A5 JP 2007509186 A5 JP2007509186 A5 JP 2007509186A5 JP 2006537550 A JP2006537550 A JP 2006537550A JP 2006537550 A JP2006537550 A JP 2006537550A JP 2007509186 A5 JP2007509186 A5 JP 2007509186A5
- Authority
- JP
- Japan
- Prior art keywords
- ache
- inhibitor
- use according
- expression
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100033639 Acetylcholinesterase Human genes 0.000 claims 20
- 108010022752 Acetylcholinesterase Proteins 0.000 claims 20
- 239000003112 inhibitor Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108091034117 Oligonucleotide Proteins 0.000 claims 5
- 239000000074 antisense oligonucleotide Substances 0.000 claims 5
- 238000012230 antisense oligonucleotides Methods 0.000 claims 5
- 108090000695 Cytokines Proteins 0.000 claims 4
- 102000004127 Cytokines Human genes 0.000 claims 4
- 239000000654 additive Substances 0.000 claims 4
- 230000000996 additive effect Effects 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 230000000770 proinflammatory effect Effects 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101150060184 ACHE gene Proteins 0.000 claims 2
- 229940124596 AChE inhibitor Drugs 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 230000001186 cumulative effect Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 230000001754 anti-pyretic effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000002221 antipyretic Substances 0.000 claims 1
- 230000036760 body temperature Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 210000001174 endocardium Anatomy 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 210000003516 pericardium Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 210000002229 urogenital system Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL158600A IL158600A (en) | 2003-10-26 | 2003-10-26 | Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent |
| IL158600 | 2003-10-26 | ||
| PCT/IL2004/000978 WO2005039480A2 (en) | 2003-10-26 | 2004-10-26 | AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509186A JP2007509186A (ja) | 2007-04-12 |
| JP2007509186A5 true JP2007509186A5 (enExample) | 2007-12-06 |
| JP4753088B2 JP4753088B2 (ja) | 2011-08-17 |
Family
ID=34044237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006537550A Expired - Fee Related JP4753088B2 (ja) | 2003-10-26 | 2004-10-26 | 抗炎症薬としてのAChEアンチセンスデオキシオリゴヌクレオチド |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20060069051A1 (enExample) |
| EP (2) | EP1682072A4 (enExample) |
| JP (1) | JP4753088B2 (enExample) |
| CA (1) | CA2543305A1 (enExample) |
| IL (1) | IL158600A (enExample) |
| WO (1) | WO2005039480A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2007399A2 (en) * | 2006-04-10 | 2008-12-31 | Ester Neurosciences Ltd. | Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases |
| US20110136897A1 (en) * | 2008-08-14 | 2011-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders |
| MX2011011517A (es) | 2009-04-29 | 2012-06-19 | Amarin Corp Plc | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. |
| CN102458109B (zh) | 2009-04-29 | 2015-02-11 | 阿马里纳制药公司 | 稳定的药物组合物和使用其的方法 |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20220102008A1 (en) * | 2020-09-30 | 2022-03-31 | Genentech, Inc. | Methods and systems for placebo response modeling |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL101600A (en) * | 1992-04-15 | 2000-02-29 | Yissum Res Dev Co | Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| AU727611B2 (en) * | 1996-12-12 | 2000-12-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them |
| AU8742198A (en) * | 1997-08-15 | 1999-03-08 | Shire International Licensing B.V. | Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity |
| IL143379A (en) | 2001-05-24 | 2013-11-28 | Yissum Res Dev Co | Oligonucleotide against human ache isoform r and its uses |
| EP2007399A2 (en) * | 2006-04-10 | 2008-12-31 | Ester Neurosciences Ltd. | Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases |
-
2003
- 2003-10-26 IL IL158600A patent/IL158600A/en not_active IP Right Cessation
-
2004
- 2004-10-26 EP EP04791840A patent/EP1682072A4/en not_active Withdrawn
- 2004-10-26 CA CA002543305A patent/CA2543305A1/en not_active Abandoned
- 2004-10-26 WO PCT/IL2004/000978 patent/WO2005039480A2/en not_active Ceased
- 2004-10-26 EP EP13153748.2A patent/EP2599489A1/en not_active Withdrawn
- 2004-10-26 JP JP2006537550A patent/JP4753088B2/ja not_active Expired - Fee Related
-
2005
- 2005-07-21 US US11/187,719 patent/US20060069051A1/en not_active Abandoned
-
2007
- 2007-04-18 US US11/788,321 patent/US20090005331A1/en not_active Abandoned
-
2013
- 2013-05-22 US US13/899,922 patent/US8722876B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cunningham et al. | The sickness behaviour and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I: C) | |
| Fonseca et al. | Use of CpG oligonucleotides in treatment of asthma and allergic disease | |
| G Drake et al. | The therapeutic potential of Toll-like receptor 7 stimulation in asthma | |
| WO2005067900A3 (en) | Azabenzofuran substituted thioureas as inhibitors of viral replication | |
| JP2012505837A5 (enExample) | ||
| Iauk et al. | Protection against murine endotoxemia by treatment with Ruta chalepensis L., a plant with anti-inflammatory properties | |
| Xu et al. | Differential expression of pro-inflammatory and anti-inflammatory genes of layer chicken bursa after experimental infection with infectious bursal disease virus | |
| UA92746C2 (en) | Thiazole compounds and methods of use | |
| Davis et al. | The neuron-specific interleukin-1 receptor accessory protein is required for homeostatic sleep and sleep responses to influenza viral challenge in mice | |
| JP2009504157A5 (enExample) | ||
| JP2009526751A5 (enExample) | ||
| JP2007533687A5 (enExample) | ||
| WO2009026292A1 (en) | Dosing methods for treating disease | |
| JP2009510044A5 (enExample) | ||
| JP2005537234A5 (enExample) | ||
| JP2007509186A5 (enExample) | ||
| JP2009513604A5 (enExample) | ||
| JP2004537500A5 (enExample) | ||
| JP2009500045A5 (enExample) | ||
| US20100016377A1 (en) | Use of a p38 Kinase Inhibitor for Treating Psychiatric Disorders | |
| WO2005095345A3 (en) | Heteroaryl guanidines as inhibitors of viral replication | |
| KR20120044937A (ko) | 약학적 제제 | |
| KR20190089005A (ko) | 에베롤리무스, 닥톨리십 또는 둘 다를 사용하여 면역 반응을 증진시키는 방법 | |
| CN101437534A (zh) | 口服干扰素的广谱免疫和抗病毒基因调节作用 | |
| CN1535724B (zh) | 重组人干扰素在制备预防严重性急性呼吸道综合征的药物的用途 |